AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 222 min read$CGC

Stewart Thomas Carlton sold $9K of CGC

Stewart Thomas Carlton (See Remarks) sold 9,285 shares of Canopy Growth Corp (CGC) at $0.97 on 2026-06-17.

Original reporting
SEC EDGAR · Stewart Thomas Carlton
Published Jun 22, 2026, 8:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 22, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CGC
Neutral
medium confidence
Mentioned
$CGC
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGCNeutralLow
01

Why it matters

The newest fact is the reported open-market sale details (shares, price, total value, post-transaction holdings).

02

Market read

Traders may note insider selling, but there is no accompanying fundamental update (earnings, guidance, deal, or regulatory action).

03

What to watch

The filing lacks context on total holdings, tax obligations, or whether other insiders are buying; traders should avoid over-weighting a single small sale.

Relevance 3/10Novelty 3/10Timing: after-hours/filing update on 2026-06-22 for a 2026-06-17 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Canopy Growth (CGC).

Company-level read

Ticker impact

$CGCNeutralMedium confidence
Context

Form 4 shows officer Stewart Thomas Carlton sold 9,285 shares of Canopy Growth at $0.9741 on 2026-06-17.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only unless paired with other disclosures.

Evidence & confidence

The filing is a disclosed sale (not a buy), but it is small relative to typical float and provides no new operational/regulatory/financial catalyst.

Market effects

Sector

Minimal; this is company-specific insider transaction disclosure with no sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales under a non-10b5-1 plan can still be driven by diversification/taxes; without follow-on buys or guidance changes, the signal may be noise.

Key entities

  • issuer
    Canopy Growth Corp

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Stewart Thomas Carlton

    Officer who sold 9,285 shares of CGC.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CGC insider trading history →

Related articles

AUG 24
$CURLFHighAI 9/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf has made an unsolicited bid for Aurora Cannabis, offering a 45% premium. Aurora has not accepted the deal. Tilray Brands and Canopy Growth are also engaging in consolidation. Aurora recently acquired Safari Flower, while Canopy bought MTL Cannabis. Tilray is diversifying into alcohol and CBD. Investors should consider risks of consolidation strategies.

aol.com3 min
AUG 21
$CURLFHighAI 8/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf (CURLF) has made an unsolicited bid for Aurora Cannabis (ACB), offering a 45% premium. Aurora's response was noncommittal. Canopy Growth (CGC) and Tilray Brands (TLRY) are also consolidating, with Tilray expanding into alcohol and CBD. Investors may benefit from acquisitions, but risks include integration challenges and leverage.

fool.com3 min
AUG 21
$CGCMedAI 8/10

Cannabis Operator CGC Rises 15% in a Month: Time to Buy, Hold or Sell?

Canopy Growth Corporation (CGC) shares rose 15% in a month after reporting Q1 fiscal 2027 earnings that beat estimates, showing revenue growth and improved margins. The company's cannabis business is improving, with increased revenues and narrowing losses. However, cash flow remains a concern, and competition in the cannabis market is stiff. Analysts have slightly improved loss estimates but maintain a 'Hold' rating.

zacks.com3 min
AUG 16
$CURLFMedAI 8/10

Curaleaf Wants to Buy Aurora Cannabis for $272 Million. Is Canopy Growth the Next Marijuana Takeover Target?

Curaleaf launched an unsolicited offer to buy Aurora Cannabis for $272 million, or $4 per share, about a 45% premium to Aurora’s 30-day VWAP, aiming for about $1.5 billion revenue, $350 million adjusted EBITDA, and $40 million annual cost synergies. The article also discusses whether Canopy Growth could be a future acquisition target, citing its turnaround and global medical cannabis platform.

yahoo.com4 min